PD1-Based TWIST1 Cancer Vaccine
- Therapeutic Biologics
- Reference No.
Key Problem and Market Opportunity
Checkpoint immunotherapy is a major breakthrough for cancer treatment, yet its efficacy is often limited against many types of malignancies.
In order to enhance the efficacy of existing immunotherapy, it may be necessary to elicit antitumor responses through active vaccination.
Cancer vaccines involve boosting and proper activation of patients’ own immune surveillance. The global cancer vaccines market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027.
TWIST1, the basic helix-loop-helix transcription factor, is associated with human mesothelioma tumorigenesis and required for the invasion and metastasis of mesothelioma in the immune-competent murine AB1 model. The programmed cell death protein 1 (PD1)- based vaccination provided prophylactic control by inducing long-lasting TWIST1-specific T cell responses against both subcutaneous and metastatic mesothelioma lethal challenges. Furthermore, while CTLA-4 blockade alone did not show any immunotherapeutic efficacy against established mesothelioma, its combination with PD1-based vaccination resulted in 60% complete remission.
Figure 1. Checkpoint Modulation Enhances the Antitumor Activity of sPD1-TWIST1 Vaccination for Curing Established Mesothelioma
Figure 2. Combination Therapy Induced Durable T Cell Immunity Responsive to an Immunodominant TWIST1 Epitope
Mol Ther Oncolytics. 2020 Mar 27; 16: 302–317. doi: 10.1016/j.omto.2020.01.009
Key Advantages of the Technology
- Eliciting long-term memory CD8+ T responses against tumors.
- Demonstrated efficacy in treating mesothelioma and breast cancer
Potential Product and Services
Cancer vaccines that enhance immunotherapy against tumors
- US Provisional Application No. 62/978,911
- Patent application submitted